14-3-3 beta Antibody (YA3955)(PBS only)
(Synonyms: HS1; GW128; YWHAA; KCIP-1; HEL-S-1)14-3-3 beta Antibody (YA3955) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to 14-3-3 beta.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, FC, ELISA
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS, pH 7.4.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:200-1:1000 | 1:200-1:1000 | 1:200-1:400 | 1:10000 |
Product Details
14-3-3 beta Antibody (YA3955) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to 14-3-3 beta.
-
Host Mouse
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 28 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 28 kDa
Purified recombinant fragment of human YWHAB (AA: 1-246) expressed in E. Coli.
affinity purified.
Non-conjugated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, pH 7.4.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13
-
Subcellular Localization
Cytoplasm; Melanosome; Vacuole membrane
-
Isoforms & Post-Translational Modification
14-3-3 beta has 2 isomers: P31946-1: 28082 Da (predicted); P31946-2: 27850 Da (predicted).
The alpha, brain-specific form differs from the beta form in being phosphorylated. Phosphorylated on Ser-60 by protein kinase C delta type catalytic subunit in a sphingosine-dependent fashion -
Subunit
Homodimer (PubMed:17717073). Interacts with SAMSN1 and PRKCE (By similarity). Interacts with AKAP13 (PubMed:21224381).
-
SwissProt ID
-
Synonyms
HS1; GW128; YWHAA; KCIP-1; HEL-S-1
Documentation
References
[1]. Obsilova V, et al. Structural insights into the functional roles of 14-3-3 proteins. Front Mol Biosci. 2022;9:1016071. [Content Brief]
[2]. Muslin AJ, et al. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889-897. [Content Brief]
[3]. Yang X, et al. Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci U S A. 2006;103(46):17237-17242. [Content Brief]
[4]. Gardino AK, et al. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol. 2011;22(7):688-695. [Content Brief]
[5]. Pennington KL, et al. The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions. Oncogene. 2018;37(42):5587-5604. [Content Brief]
[6]. Li Z, et al. 14-3-3σ, the double-edged sword of human cancers. Am J Transl Res. 2009;1(4):326-340. [Content Brief]
[7]. Maksymowych WP, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41(11):2104-2113. [Content Brief]
[8]. Aghazadeh Y, et al. The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discov Today. 2016;21(2):278-287. [Content Brief]